Risk of cancer in patients with psoriasis on biological therapies: a systematic review
ConclusionsThere were important limitations to the studies identified including choice of comparator arms, inadequate adjustment for confounding factors and failure to account for latency periods of cancer. There remains a need for ongoing pharmacovigilance in relation to cancer risk and biological therapy; the NMSC signal requires further investigation to determine the risk specifically attributable to biological therapy using prospectively collected data with adjustment for known NMSC risk factors.
Source: British Journal of Dermatology - Category: Dermatology Authors: E. Peleva, L.S. Exton, K. Kelley, C.E. Kleyn, K.J. Mason, C.H. Smith Tags: Systematic Review Source Type: research
More News: Arthritis | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Databases & Libraries | Dermatology | Lymphoma | Melanoma | Nonmelanoma Skin Cancer | Psoriasis | Rheumatoid Arthritis | Rheumatology | Skin | Skin Cancer | Squamous Cell Carcinoma | Stelara | Study | UK Health | USA Health